Inventia Technologies Spółka z Ograniczoną Odpowiedzialnością (KRS 0000428330, NIP 7543065504) is a Polish company, headquartered in Opole, Opolskie voivodeship. INVENTIA TECHNOLOGIES operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since July 30, 2012. INVENTIA TECHNOLOGIES's most recently reported net revenue was 248.3 K PLN for 2025.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Inventia Technologies
Identity
- Name
- Inventia Technologies Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- July 30, 2012
- Registry status as of
- June 10, 2026
- Latest entry
- June 10, 2026
- Founding act
- 10.07.2012R., KN R. PALEJ W OPOLU, REP. A NR 8487/2012
Articles of association history (1)
- July 10, 2012: 10.07.2012R., KN R. PALEJ W OPOLU, REP. A NR 8487/2012
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- BUDOWLANYCH, 64, 45-123, OPOLE, POLSKA
- Voivodeship
- OPOLSKIE
- District
- M. OPOLE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-97676-12224-EIFVS-25
Risk and payment profile - Inventia Technologies
Credibility rating
25.9 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
19
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
4
4/14 yrs
Board changes
0
0/14 yrs
PKD changes
1
1/14 yrs
Name changes
0
0/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: E (26/100)
Trend: deteriorating (-12.2 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2025
Current: 2.5 K PLN
Safe: 355.33 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Inventia Technologies
Founded
July 30, 2012
13 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
OPOLE
OPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
450.0 K PLN
4,500 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
8 years
2018–2025 · profitable: 6/8
Registry entries
31
latest: June 10, 2026
Risk signals
Revenue
248.3 K PLN
2025
Net profit
-163.2 K PLN
2025
Assets
667.5 K PLN
2025
Equity
248.4 K PLN
2025
EBITDA
62.3 K PLN
2025
Valuation
50.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Inventia Technologies.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
